Table of Contents

HK J Paediatr (New Series)
Vol 6. No. 2, 2001

HK J Paediatr (New Series) 2001;6:110-115

Original Article

Treatment of Paediatric Cancers in Hong Kong: An Interim Report

CK Li, GCF Chan, KW Chik, SY Ha, YL Lau, ACW Lee, CY Lee, CK Li, SC Ling, CW Luk, MMK Shing, HL Yuen, PMP Yuen


The Hong Kong Paediatric Haematology and Oncology Study Group conducted clinical studies on treatment of various paediatric cancers in Hong Kong. This article reported the treatment result of the various cancers presented in the annual workshop in February 2000. The five-year overall survival and event free survival were 80.2% and 62% for Acute Lymphoblastic Leukaemia, and were 60% and 53% for Acute Myeloid Leukaemia respectively. The other cancers with shorter follow up had three years overall and event free survival as follow: 75% and 62% for Medulloblastoma, 74% and 67% for Non-Hodgkin Lymphoma, 100% and 91% for extracranial Germ Cell Tumour, 30% and 20% for advanced neuroblastoma, 68% and 52% for Ewing's Sarcoma, 87% and 79% for Wilms' Tumour, 82% and 80% for Osteosarcoma, 56% and 45% for Rhabdomyosarcoma, and 60% and 50% for Hepatoblastoma respectively. The protocols had a high rate of adoption by the various hospitals, over 95% eligible patients were treated according to protocols. The toxicity of these protocols was acceptable with treatment related mortality less than 5% in most protocols.

Keyword : Overall and event free survival

Abstract in Chinese


This web site is sponsored by Johnson & Johnson (HK) Ltd.
©2023 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.